200 results about "Carrier protein" patented technology

The invention discloses a test strip for detecting etoxazole and application of the test strip. The test strip comprises a sample absorption pad (1), a conjugate release pad (2), a reaction film (3), a water absorption pad (4) and a bottom plate (7), the reaction film is provided with a detection line (5) coated with an etoxazole hapten-carrier protein conjugate and a quality control line (6) coated with a goat anti-mouse antibody, and the conjugate release pad (2) is sprayed with an etoxazole monoclonal antibody-colloidal gold marker. The invention also provides a method for detecting residual etoxazole in vegetables and fruits by using the etoxazole test strip. The test strip provided by the invention has the characteristics of simplicity in operation, high sensitivity, high detection speed, low cost and the like, and is suitable for screening and on-site monitoring of a large number of samples.

The invention provides a safrole hapten and application of the safrole hapten in detection of safrole through immunoassay. The structure of the safrole hapten is shown in the specification. The two safrole haptens provided by the invention have spacer arms with proper lengths, and after the safrole haptens are coupled with carrier protein, the haptens can be fully exposed, and recognition of the spacer arms can be avoided as much as possible. The safrole hapten is used for preparing an artificial antigen and an antibody, and the obtained safrole monoclonal antibody is high in titer, strong in specificity and high in affinity. An immunoassay method constructed on the basis of the safrole artificial antigen and antibody has high specificity and sensitivity, the lowest detection limit LOD is 0.09 ng / mL, the half inhibitory concentration IC50 is 2.05 ng / mL, the quantitative detection range is 0.28-14.89 ng / mL, no cross reaction exists on safrole analogues, and rapid qualitative and quantitative detection can be conducted on safrole in a sample.

The present disclosure provides lysosomal targeting bifunctional molecules that target disease causing anti-TSHR autoantibodies for degradation. The lysosomal targeting bifunctional molecules include a ligand moiety that specifically binds to an asialoglycoprotein receptor (ASGPR), and which is linked via a carrier protein to a thyroid stimulating hormone receptor (TSHR) polypeptide that specifically binds target anti-TSHR autoantibodies.

The invention discloses a phthalimidic acid hapten, an artificial antigen, an antibody, and a preparation method and application of the phthalimidic acid hapten and the artificial antigen. The structure of the phthalimide acid hapten is shown as a formula (I), and the phthalimide acid hapten is obtained by introducing a carboxyl active group with a spacer arm with a certain length to carboxyl of phthalimide acid, so that the phthalimide acid hapten can be coupled with carrier protein to obtain an artificial antigen for immunization; the phthalimide hapten retains all characteristic groups of the phthalimide, the original structural characteristics of the phthalimide are changed to the minimum extent, and a foundation is laid for generating an antibody with higher specificity and higher sensitivity for subsequently stimulating animal immune response. An artificial antigen and a phthalimide acid monoclonal antibody are prepared through the hapten, indirect competitive ELISA based on the monoclonal antibody has the lowest detection limit of phthalimide acid of 2.44 ng / mL, IC50 of 17.29 ng / mL and the linear range of 5.02-59.51 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention discloses a method for improving the water-retaining property of meat paste, which specifically comprises the following steps: firstly, sufficiently tumbling and chopping fresh meat paste to be treated at low temperature, and adjusting the pH value of the meat paste to be neutral; then, protein-phospholipid composite emulsion is added into the meat paste, the protein-phospholipid composite emulsion is prepared by mixing phospholipid extracted from livestock and poultry head tissues, a carrier protein solution and algal polysaccharides, then mixing the mixture with edible oil, performing ultrasonic treatment, emulsifying and homogenizing, and finally, a small amount of the protein-phospholipid composite emulsion is added into the pretreated meat paste for many times, and homogenizing at high pressure, adding transglutaminase, and packaging in vacuum. The method is simple, the steps are easy to operate, the pH value of the meat paste can be reduced, the loss rate of juice in the meat paste can be reduced, the water-retaining property of the meat paste can be improved, and meanwhile, the structural stability of the meat paste can be enhanced by improving the combination of fat and water.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition for preventing pneumococcal and varicella-zoster virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate immunogenic composition. The immunogenic composition of the present invention comprises: at least one pneumococcal polysaccharide-protein conjugate wherein the pneumococcal polysaccharide is linked to a carrier protein through a covalent bond; the carrier protein is varicella-zoster virus glycoprotein E, namely VZV gE recombinant protein, and the amino acid sequence of the VZV gE recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. The immunogenic composition containing the multivalent pneumococcal polysaccharide-protein conjugate, provided by the invention, shows a remarkable synergistic interaction effect, and realizes a'dual enhancement 'effect.

The present invention relates to a recombinant organism or microorganism having a decreased pool of crotonic acid compared to the organism or microorganism from which it is derived due to at least one of: (i) an increased conversion of crotonyl-CoA into butyryl-CoA; and / or an increased conversion of butyryl-CoA into butyric acid; (ii) an increased conversion of crotonyl-CoA into 3-hydroxybutyryl-CoA; and / or an increased conversion of 3-hydroxybutyryl-CoA into 3-hydroxybutyric acid; (iii) an increased conversion of crotonic acid into crotonyl-CoA; (iv) an increased conversion of crotonyl-[acyl-carrier protein] into butyryl [acyl-carrier-protein]; (v) a decreased conversion of crotonyl-CoA into crotonic acid; and / or (vi) a decreased conversion of crotonyl-[acyl-carrier protein] into crotonic acid. Moreover, the present invention relates to the use of such a recombinant organism or microorganism for the production of alkenes with the enzyme ferulic acid decarboxylase. Further, the present invention relates to a method for the production of isobutene or butadiene by culturing such a recombinant organism or microorganism in a suitable culture medium under suitable conditions.

The invention discloses a carrier protein with an adjuvant function and application thereof. The carrier protein with the adjuvant function has a sequence as shown in SEQ ID NO. 1. According to the carrier protein with the adjuvant function, a part of sequence is intercepted from the flagellin FliC of Burkholderia cepacia, so that the adjuvant activity of the flagellin is reserved, and the immunogenicity and antigenicity of the flagellin are reduced; when being applied to a fusion protein or a small-molecule drug, the fusion protein or the small-molecule drug can enhance the immunogenicity, so that the fusion protein or the small-molecule drug has important significance on subunit vaccines, polypeptide vaccines or small-molecule drug carriers.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and / or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The invention discloses a specific antibody for detecting cathepsin S, a kit and application. The specific antibody for detecting cathepsin S is prepared by coupling a cathepsin S specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The specific antibody for detecting cathepsin S can specifically detect cathepsin S, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or curative effect evaluation of the chronic obstructive pulmonary disease, the marker has good diagnosis sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of the chronic obstructive pulmonary disease, and is worthy of popularization and application. The method has important significance and clinical application value for diagnosis and treatment of chronic obstructive pulmonary diseases.

The present invention relates to novel oligosaccharide-carrier protein conjugates of formula (I) and their use as pharmaceuticals, particularly as vaccines. The present invention also relates to related aspects, including oligosaccharide intermediates of formulas (II) and (III) and methods for preparing such conjugates. Furthermore, the present invention relates to pharmaceutical compositions comprising the oligosaccharide-carrier protein conjugates and to the use of oligosaccharide-carrier protein conjugates of formula (IV) in biological assays. [Formula 1] JPEG2025536393000131.jpg85168

The application discloses a kind of areca alkaloid artificial hapten, artificial antigen and its preparation method and application, with norarecoline hydrochloride as the starting material for synthesizing artificial hapten.This areca alkaloid artificial hapten retains the characteristic structure of areca alkaloid to the greatest extent, and has active groups that can couple with carrier proteins, which can be used as antigenic determinants;Further, the areca alkaloid artificial antigen obtained can be used to immunize to obtain an anti-areca alkaloid artificial antibody with high affinity, high sensitivity and strong specificity.The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:70000, and can be used for rapid and accurate immunodetection and immunoassay of areca alkaloid.

The invention belongs to the field of food science and technology, and discloses high-activity protein powder enriched with seaweed nano polyphenol and a preparation process of the high-activity protein powder. According to the protein powder, the seaweed nano polyphenol with the average particle size of 20-100 nm is prepared by taking preferable brown seaweed as a raw material through the steps of enzymolysis, ultrasonic treatment, membrane separation, high-pressure homogenization and the like. Meanwhile, carrier protein is subjected to heat treatment and enzymatic reaction to form protein nano carrier particles, and seaweed nano polyphenol is encapsulated in the protein nano carrier particles by adopting an electrostatic layer-by-layer self-assembly technology. In addition, protein raw materials are subjected to enzymolysis by compound protease to obtain small molecule peptide fragments, so that the solubility and the digestibility are improved. And finally, mixing a high-activity peptide solution with the protein-polyphenol nano-composite, and freeze-drying. The product has the advantages of high activity, easiness in digestion, no bitter taste and the like.

This invention belongs to the field of immunology and discloses a hybridoma cell line and the preparation and application of its secreted monoclonal antibody that uniformly recognizes tylosin / tilmicosin. The monoclonal antibody hybridoma cell line is named DES-AOAA-14D5, with accession number CGMCC NO: 45303. This invention utilizes decarboxymethyl tylosin and oxycarboxymethyl hydroxylamine to synthesize a hapten, conjugates a carrier protein to prepare a complete antigen, immunizes mice, and, through cell fusion and screening techniques, prepares a hybridoma cell line that can secrete a monoclonal antibody that uniformly recognizes tylosin / tilmicosin. IC50 50 The effective concentrations were 1.59 and 1.72 ng / mL, respectively, with a cross-reactivity rate as high as 92.44%. An immunoassay method for the simultaneous and accurate detection of tylosin / tilmicosin in milk was established using this antibody. The cut-off value for both tylosin and tilmicosin was 16 ng / mL, and no cross-reactivity was observed with other structural analogs. The detection method of this invention shows promising application prospects.

The present invention relates to improved pharmaceutical compositions comprising one or more bioconjugate compositions. Each bioconjugate composition comprises a mixture of mono- and multi-glycosylated bioconjugates of a specific Escherichia coli (E. coli) O-antigen polysaccharide covalently attached to a Pseudomonas aeruginosa exoprotein A carrier protein. The present invention further relates to methods for producing purified bioconjugates from Gram-negative host cells, and bioconjugates obtainable or obtainable by said methods.

The invention discloses a kit and a method for extracting nucleic acid from an ophthalmic sample and application of the kit and the method in metagenome sequencing. A method of extracting nucleic acid from an ophthalmic sample includes extracting nucleic acid from the ophthalmic sample using a sample processing system comprising the ophthalmic sample, a carrier RNA, protease K, and a lysis reagent. According to the method, a carrier RNA is added to prevent loss of trace nucleic acid, high-concentration protease K is adopted to enhance digestion of protein, and a chemical reagent is adopted to lyse cells, so that excessive damage and degradation of nucleic acid and low-volume elution caused by severe oscillation of mechanical wall breaking are avoided, and the final concentration of nucleic acid is improved.

The invention belongs to the technical field of functional food and active substance delivery, and relates to EGCG (epigallocatechin gallate) loaded protein-polysaccharide ternary composite nanoparticles and a preparation method thereof. Zein is used as carrier protein, Arabic gum is used as stable polysaccharide, and an anti-solvent precipitation method is combined with ultrasonic treatment to prepare the composite nanoparticles. The preparation method specifically comprises the following steps: dissolving zein in an ethanol water solution to form an organic phase, dissolving Arabic gum in a water phase, adding the water phase into the organic phase under a stirring condition, removing ethanol to obtain a zein-Arabic gum binary composite nanoparticle dispersion liquid, introducing EGCG, and carrying out ultrasonic-assisted loading and drying to obtain a target product. The encapsulation efficiency of the active substance is improved through the ultrasonic-anti-solvent synergistic effect, the thermal stability and storage stability of the system are improved, and the method is simple, good in repeatability and suitable for delivery of food-grade active ingredients.

The present application belongs to the technical field of bio-chemical industry, and particularly relates to a lorcaserin artificial hapten, a lorcaserin artificial antigen, and a preparation method and application thereof. The lorcaserin hydrochloride is used as a starting material for synthesizing the artificial hapten, the lorcaserin artificial hapten of the present application retains the characteristic structure of lorcaserin to the greatest extent, and has an active group which can be coupled with a carrier protein, and can be used as an antigenic determinant; the lorcaserin artificial antigen prepared further can be used for immunization to obtain an anti-lorcaserin artificial antibody with high affinity, high sensitivity and high specificity, the titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:256000, and the immune serum can be used for rapid and accurate immunodetection and immunological analysis of lorcaserin.

The present invention relates to a conjugate comprising an mRNA of an antigen protein and an mRNA encoding a carrier protein linked to the 5'terminal and the 3 'terminal of the mRNA of the antigen protein, and an vaccination composition and / or a vaccine composition comprising the conjugate, the present invention having an effect of stably increasing the expression of an antigen protein.

This invention relates to a medemididine hapten, a complete antigen, and their preparation methods and applications. The structure of the medemididine hapten is shown in Formula I. The preparation method of the medemididine hapten includes: (1) substituting medemididine with ethyl 3-bromopropionate to obtain intermediate 2; (2) adding sodium hydroxide to deprotect the ester group to obtain medemididine hapten 3. The structure of the complete antigen is shown in Formula II. The preparation method of the complete antigen includes: coupling the medemididine hapten with a carrier protein to obtain the complete antigen. This invention discloses a method for preparing medemididine hapten and complete antigen. The synthesis steps are simple and effective, and it can be used in immunoassay. Among them, colloidal gold immunochromatography is simple to operate, has a short detection time, high specificity, and good reproducibility, which can meet the domestic demand for immunoassay of medemididine.

The invention relates to the technical field of small molecule chemical detection, in particular to a raclosibin artificial hapten, an artificial antigen and a preparation method and application of the raclosibin artificial hapten and the artificial antigen. The invention provides a raclosibin artificial hapten with a chemical structure as shown in a formula I. The artificial hapten maximally retains a characteristic structure of raclosibin, has an active group capable of being coupled with carrier protein, can be used as an antigenic determinant, and is high in sensitivity during immunoassay; the invention provides a raclosibin artificial antigen based on the raclosibin artificial hapten, and the raclosibin artificial antigen can be applied to colloidal gold immunochromatography detection of raclosibin and has relatively high sensitivity, detection gradient and relatively good specificity.

The invention belongs to the field of medicines, and relates to a gamma delta T cell containing a chimeric antigen receptor EGFR-CCR6-E27CAR. The chimeric antigen receptor comprises a single-chain antibody ScFv of a targeted EGFR (epidermal growth factor receptor), a CD8 hinge region, a CD8 transmembrane region, 4-1BB, a CD3 zeta chain, CCR6 and a secreting type ScFv of a targeted PD-1. The invention also comprises a protein and a nucleic acid sequence of the chimeric antigen receptor, and a preparation method and application of the vector, the protein, the nucleic acid and the cell. In an in-vitro cell model and an in-vivo mouse, the CAR-gamma delta T cell disclosed by the invention shows relatively strong tumor cell killing ability, can remarkably control in-vivo growth of tumors and remarkably prolong the lifetime of the mouse, and lays a foundation for the development of drugs for long-term control of in-vivo tumors of patients.

The invention belongs to the technical field of synthesis of polysaccharide conjugate vaccines, and relates to a proteus mirabilis O3a O-antigen tetrasaccharide repeating unit containing an adamantane skeleton, an antigen and a polysaccharide conjugate vaccine. The active ingredients of the polysaccharide conjugate vaccine provided by the invention comprise a subject and an object, and the subject and the object are mutually combined through non-covalent interaction; the subject comprises a compound of beta-cyclodextrin and carrier protein, and the guest comprises maltotriose containing an adamantane skeleton or a proteus mirabilis O3a O-antigen containing an adamantane skeleton. The proteus mirabilis O3a O-antigen tetrasaccharide repeating unit containing the adamantane skeleton is successfully synthesized with high stereoselectivity and excellent yield by adopting a [2 + 1 + 1] graded assembly strategy, and the research can lay a firmer theoretical and practical foundation for research and development of proteus mirabilis resistant vaccines.

The invention relates to a serum-free culture medium with limited chemical components for mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. The culture medium comprises a basic culture medium, growth factors and a carrier protein stabilizer, the growth factors comprise a proliferation promoting factor, an activating agent, a signal factor and nutrients; the activating agent comprises Wnt7a protein and LIF protein. According to the invention, Wnt7a, LIF, Noggin, Activin A and TGF-beta3 are combined together according to a specific concentration and proportion (especially Wnt7a and LIF) for the first time, and cooperate with other factors (FGF-2 and IGF-1) to construct a brand new signal network capable of simulating an in-vivo dry microenvironment.